for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vascular Biogenics Ltd

VBLT.OQ

Latest Trade

1.76USD

Change

-0.02(-1.12%)

Volume

5,878

Today's Range

1.74

 - 

1.77

52 Week Range

1.02

 - 

3.17

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Vbl Therapeutics Provides Corporate Update

March 25 (Reuters) - Vascular Biogenics Ltd <VBLT.O>::VBL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.VASCULAR BIOGENICS - AS OF DEC 31, 2020, HAD CASH, CASH EQUIVALENTS, SHORT-TERM BANK DEPOSITS AND RESTRICTED BANK DEPOSIT TOTALING $30.8 MILLION.VASCULAR BIOGENICS - EXPECTS CASH, CASH EQUIVALENTS, SHORT-TERM BANK DEPOSITS WILL BE ENOUGH TO FUND OPERATING EXPENSES, CAPEX REQUIREMENTS INTO Q4 2022.

VBL Therapeutics Says Data Safety Monitoring Committee Provides Green Light To Advance Oval Phase 3 Registration Enabling Study Of Vb-111 In Ovarian Cancer

Feb 22 (Reuters) - Vascular Biogenics Ltd <VBLT.O>::VBL THERAPEUTICS ANNOUNCES DATA SAFETY MONITORING COMMITTEE PROVIDES GREEN LIGHT TO ADVANCE THE OVAL PHASE 3 REGISTRATION ENABLING STUDY OF VB-111 IN OVARIAN CANCER.VASCULAR BIOGENICS LTD - COMMITTEE FOUND NO SAFETY ISSUES WITH TRIAL AND RECOMMENDED ITS CONTINUATION AS PLANNED..VASCULAR BIOGENICS LTD - TRIAL CONTINUES TO ENROLL ON TRACK IN US, EUROPE AND ISRAEL.

VBL Therapeutics Reports Third Quarter 2020 Financial Results And Provides Corporate Update

Nov 16 (Reuters) - Vascular Biogenics Ltd <VBLT.O>::VBL THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.VASCULAR BIOGENICS LTD - EXPECTS CASH, CASH EQUIVALENTS AMONG OTHERS TO BE SUFFICIENT TO FUND OPERATING EXPENSES AND CAPEX NEEDS INTO Q3 OF 2022.VASCULAR BIOGENICS LTD QTRLY REVENUES WERE $193 THOUSAND VERSUS $79 THOUSAND.VASCULAR BIOGENICS LTD QTRLY LOSS PER ORDINARY SHARE $0.12.VASCULAR BIOGENICS LTD - INVESTIGATOR SPONSORED VB-111 PHASE 2 STUDIES, IN RGBM IS ON TRACK FOR INITIATION.

Vbl Therapeutics Announces Q2 Loss Per Share $0.14

Aug 13 (Reuters) - Vascular Biogenics Ltd <VBLT.O>::VBL THERAPEUTICS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.14.Q2 EARNINGS PER SHARE ESTIMATE $-0.14 -- REFINITIV IBES DATA.

Vascular Biogenics files Prospectus Relates To Resale By Selling Shareholders Of Up To 11.5 Million Ordinary Shares That Are Issuable Upon Exercise Of Warrants

June 1 (Reuters) - Vascular Biogenics Ltd <VBLT.O>::VASCULAR BIOGENICS-PROSPECTUS RELATES TO RESALE BY SELLING SHAREHOLDERS OF UP TO 11.5 MILLION ORDINARY SHARES THAT ARE ISSUABLE UPON EXERCISE OF WARRANTS.VASCULAR BIOGENICS SAYS SELLING SHAREHOLDERS MAY OFFER THE SHARES FROM TIME TO TIME THROUGH PUBLIC OR PRIVATE TRANSACTIONS - SEC FILING.

Vascular Biogenics Q1 Loss Per Share $0.15

May 14 (Reuters) - Vascular Biogenics Ltd <VBLT.O>::VBL THERAPEUTICS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.15.Q1 REVENUE $366,000 VERSUS $219,000.Q1 REVENUE ESTIMATE $162,000 -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE ESTIMATE $-0.17 -- REFINITIV IBES DATA.

VBL Therapeutics Announces Positive Outcome Of Interim Analysis In Oval Phase 3 Ovarian Cancer Pivotal Study

March 26 (Reuters) - Vascular Biogenics Ltd <VBLT.O>::VBL THERAPEUTICS ANNOUNCES POSITIVE OUTCOME OF INTERIM ANALYSIS IN OVAL PHASE 3 OVARIAN CANCER PIVOTAL STUDY.VASCULAR BIOGENICS LTD - OVERALL CA-125 RESPONSE RATE IN FIRST 60 RANDOMIZED EVALUABLE PATIENTS IS 53%.VASCULAR BIOGENICS LTD - OVAL DSMC REVIEWED UN-BLINDED DATA AND DETERMINED THAT STUDY HAS MET INTERIM PRE-SPECIFIED CRITERION.VASCULAR BIOGENICS LTD - DSMC RECOMMENDS THAT STUDY PROCEED WITHOUT MODIFICATION..VASCULAR BIOGENICS- CA-125 RESPONSE RATE OBSERVED IN PHASE 3 INTERIM ANALYSIS IS AT LEAST AS GOOD AS RESPONSE RATE SEEN IN PHASE 2.

Vbl Therapeutics Announces Year Ended December 31, 2019 Financial Results And Provides Corporate Update

March 19 (Reuters) - Vascular Biogenics Ltd <VBLT.O>::VBL THERAPEUTICS ANNOUNCES YEAR ENDED DECEMBER 31, 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.VASCULAR BIOGENICS - EXPECTS CASH, CASH EQUIVALENTS, SHORT-TERM BANK DEPOSITS WILL BE SUFFICIENT TO FUND OP EXPENSES, CAPEX REQUIREMENTS INTO 3Q 2021.

VBL Therapeutics Q3 Loss Per Share $0.14

Nov 14 (Reuters) - Vascular Biogenics Ltd <VBLT.O>::VBL THERAPEUTICS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.14.Q3 EARNINGS PER SHARE ESTIMATE $-0.14 -- REFINITIV IBES DATA.VASCULAR BIOGENICS- AT SEPT 30, HAD CASH, CASH EQUIVALENTS, SHORT-TERM BANK DEPOSITS AND RESTRICTED BANK DEPOSITS TOTALING $41.1 MILLION.VASCULAR BIOGENICS- EXPECTS CASH, CASH EQUIVALENTS & SHORT-TERM BANK DEPOSITS SUFFICIENT TO FUND OPERATING EXPENSES,CAPEX REQUIREMENTS FOR ABOUT 2 YRS.

VBL Therapeutics Announces New IND For An Investigator-Sponsored Phase 2 Trial Of VB-111 In Recurrent Glioblastoma

Nov 6 (Reuters) - Vascular Biogenics Ltd <VBLT.O>::VBL THERAPEUTICS ANNOUNCES NEW IND FOR AN INVESTIGATOR-SPONSORED PHASE 2 TRIAL OF VB-111 IN RECURRENT GLIOBLASTOMA.VASCULAR BIOGENICS LTD - IND FOR PHASE 2 TRIAL OF VB-111 IN RECURRENT GLIOBLASTOMA RECEIVED CLEARANCE FROM U.S. FDA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up